Abstract
Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are both efficacious in treating well-selected patients who have hepatocellular carcinoma (HCC). The sequential combination of these two modalities has a sound theoretical basis and raises the probability of complete local response in tumors that are beyond the size at which the likelihood of failure with RFA alone begins to rise. Cheng et al. have found that when limited to patients with well-compensated liver disease, combined TACE and RFA does not seem to dramatically increase the risk of complications beyond the risk levels associated with the individual procedures. The survival benefit demonstrated in this recent article is, however, an artifact of a rigid study design that did not allow rational selection of treatment on the basis of individual patient and tumor characteristics. This study bolsters the evidence that the combination of TACE with RFA enhances local response, strengthening the status of nonsurgical treatment compared with resection for the treatment of early HCC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Llovet JM et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734–1739
Lo CM et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164–1171
Lin SM et al. (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127: 1714–1723
Rossi S et al. (2000) Percutaneous radiofrequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217: 119–126
Cheng BQ et al. (2008) Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 299: 1669–1677
Mazzaferro V et al. (2004) Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation. Ann Surg 240: 900–907
Chen MS et al. (2007) Local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243: 321–328
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Schwartz, M., Weintraub, J. Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma. Nat Rev Clin Oncol 5, 630–631 (2008). https://doi.org/10.1038/ncponc1216
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1216
This article is cited by
-
Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study
Hepatology International (2012)
-
Silicon Carbide as a Heat-enhancing Agent in Microwave Ablation: In Vitro Experiments
CardioVascular and Interventional Radiology (2011)
-
Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms
Onkopipeline (2008)